Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma
Oncology Research · 2025
DOI: 10.32604/or.2025.065319 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Prin Sungwan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honj…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Erb-b2 Receptor Tyrosine Kinases, Bile Duct Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited. The human epidermal growth factor receptor 2 (HER2) plays an oncogenic role by promoting an aggressive cancer phenotype through multiple pathways. While HER2 has shown increasing potential as an effective target for breast and gastric cancers over the last decade, this has not been the case for CCA. This review explores the possibility of targeting HER2 in CCA immunotherapy. Key findings suggest that HER2 alterations have been reported as one of the signatures associated with a poorer prognosis in liver fluke-associated CCA, the most prevalent subtype in Southeast Asia. Furthermore, we assess recent advances in HER2-targeted therapeutic approaches, presenting the current stage, rationale, and evidence supporting the use of HER2 as a promising therapeutic target for cancer immunotherapy in CCA. We also emphasize the crucial role of animal models in developing anticancer therapies. In summary, focusing on HER2 expression could provide alternative strategies for the HER2-altered CCA cluster.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
- Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
- Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, 50200, Thailand.
Zitieren
APA
Sungwan, P., Panaampon, J., Sumankan, R., Aoki, G., & Okada, S. (2025). Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma. Oncology Research. https://doi.org/10.32604/or.2025.065319
Vancouver
Sungwan P, Panaampon J, Sumankan R, Aoki G, Okada S. Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma. Oncology Research. 2025. doi:10.32604/or.2025.065319
BibTeX
@article{Sungwan2025,
author = {Sungwan, Prin and Panaampon, Jutatip and Sumankan, Ratchaneewan and Aoki, Genki and Okada, Seiji},
title = {Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.065319}
}
EUVIMED